Skip to content
Journal article

Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.

Current opinion in investigational drugs (London, England : 2000), vol. 7, issue 10 (2006) pp. 924-935

  • 4

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.
  • N/A

    Views

    ScienceDirect users who have downloaded this article.
Sign in to save reference

Abstract

Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.

Find this document

Authors

  • Mary Courtney Moore

Cite this document

Choose a citation style from the tabs below